15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis

Vesicoureteral Reflux, Posterior Urethral Valves & Paediatric Nocturnal Enuresis

Congenital and functional lower urinary tract disorders in children span a clinical spectrum from relatively benign primary vesicoureteral reflux (VUR) and paediatric nocturnal enuresis to catastrophic congenital lower urinary tract obstruction (LUTO) caused by posterior urethral valves (PUV). Mastery of the pathophysiological mechanisms, diagnostic pathways (MCUG vs DMSA scintigraphy, voiding diaries), emergency stabilization protocols, long-term renal prognostic factors, and evidence-based stepped behavioral and pharmacological urotherapy is mandatory for European Board of Urology (FEBU) certification per European Association of Urology (EAU) and European Society for Paediatric Urology (ESPU) Guidelines.

---

1. Vesicoureteral Reflux (VUR)

Vesicoureteral reflux is the retrograde regurgitation of urine from the bladder into the upper urinary tract. Affecting approximately 1% of all children and up to 30% to 50% of children presenting with acute febrile urinary tract infections (UTIs), VUR is a primary risk factor for reflux nephropathy, hypertension, and chronic kidney disease.

Functional Anatomy of the Anti-Reflux Mechanism

The ureter traverses the bladder wall obliquely through the detrusor muscle, forming the intramural ureter, and continues beneath the urothelium as the submucosal ureteric tunnel before terminating at the ureteral orifice on the trigone:

• In a normal bladder, the ratio of submucosal tunnel length to ureteric diameter is approximately 5:1.
• As the bladder fills and intravesical storage pressure rises, the pliable submucosal tunnel is passively compressed against the muscular backing of the detrusor, creating a mechanical passive flap-valve that prevents retrograde flow.
• During active detrusor contraction during micturition, active contraction of the longitudinal muscle fibers of the trigone and ureter stretches and flattens the tunnel, sealing the orifice.
• Primary VUR results from congenital lateral displacement of the ureteric bud during embryogenesis, leading to a shortened, perpendicular intramural tunnel with a length-to-diameter ratio below 3:1.
• Secondary VUR is caused by elevated intravesical pressures that overwhelm a structurally normal junction, such as neurogenic detrusor-sphincter dyssynergia, posterior urethral valves, or severe Bladder and Bowel Dysfunction (BBD).

International VUR Grading Classification

The International Reflux Study in Children established the five-tier anatomical grading system evaluated on fluoroscopic micturating cystourethrography (MCUG / VCUG):

+----------------------------------------------------------------------------------------------------+
|                                 INTERNATIONAL VUR CLASSIFICATION                                   |
|                                                                                                    |
|  Grade I   --> Reflux into ureter only; no pelvicalyceal dilation                                  |
|  Grade II  --> Reflux into ureter, renal pelvis, and calyces; no dilation; sharp calyceal fornices |
|  Grade III --> Mild-to-moderate dilation of ureter and renal pelvis; mild blunting of fornices     |
|  Grade IV  --> Moderate tortuosity and dilation of ureter and pelvis; complete obliteration of     |
|                sharp angles, but papillary impressions preserved                                   |
|  Grade V   --> Gross dilation and severe tortuosity of ureter; massive pelvicalyceal dilation;     |
|                loss of papillary impressions; frequent intrarenal reflux                           |
+----------------------------------------------------------------------------------------------------+

Diagnostic Workup: MCUG vs. DMSA Scintigraphy

• Micturating / Voiding Cystourethrography (MCUG / VCUG):
  • The gold standard diagnostic modality for establishing the presence and anatomical grade of VUR.
  • Allows precise visualization of the bladder neck, urethra (vital in boys to rule out posterior urethral valves), presence of diverticula, and intrarenal reflux during filling and active voiding phases.
• 99mTc-Dimercaptosuccinic Acid (DMSA) Renal Scintigraphy:
  • The gold standard for detecting renal cortical parenchymal damage and scarring.
  • DMSA binds to proximal tubular cells; areas of decreased uptake indicate non-functioning parenchyma.
  • Congenital dysplasia may produce a small kidney with reduced, heterogeneous uptake; acquired scars often have focal defects with cortical volume loss. These patterns overlap, and dysplasia and scarring can coexist. Correlate DMSA with ultrasound morphology, prenatal/baseline findings, infection history and follow-up rather than inferring cause from a single scan.
  • For permanent post-infection scarring, assess at about 6 months after the UTI; acute inflammatory defects may recover. DMSA may also be used earlier for a different question, such as acute pyelonephritis.

Bladder and Bowel Dysfunction (BBD)

Bladder and Bowel Dysfunction (dysfunctional elimination syndrome)—characterized by symptoms such as daytime wetting, urgency, infrequent voiding, and constipation—is present in over 40% of toilet-trained children with VUR. High storage pressures and pelvic floor muscle overactivity impede the spontaneous resolution of reflux and multiply the risk of breakthrough pyelonephritis. Aggressive treatment of BBD (timed voiding, urotherapy, laxatives, and behavioral biofeedback) is mandatory and can lead to spontaneous reflux resolution in a large proportion of cases without requiring surgery.

Management Paradigms: Conservative, Endoscopic, and Surgical

Treatment choices depend on the child's age, gender, VUR grade, presence of renal scarring, and clinical course:

1. Conservative Management:

   • Spontaneous Resolution: EAU reports resolution in nearly 80% of grades I–II and 30–50% of grades III–V over 4–5 years. Age, laterality, BBD and presentation matter; bilateral high-grade reflux resolves less readily.
   • Watchful Waiting & Continuous Antibiotic Prophylaxis (CAP): Use a risk-based approach. Observation with prompt UTI assessment may suit selected low-risk children; CAP benefits those at higher infection risk, including young infants, dilating reflux or BBD. Select an age-appropriate agent and weight-based prophylactic dose, such as trimethoprim, nitrofurantoin or an appropriate beta-lactam. CAP reduces recurrent UTIs but has not clearly reduced new renal scarring; resistance is a trade-off. Treat BBD and monitor rather than prescribing prophylaxis solely from the reflux grade.

2. Endoscopic Subureteric Bulking Injection (Deflux):

   • Minimally invasive day-case procedure using dextranomer/hyaluronic acid copolymer (Deflux) beads.
   • Techniques:
     • STING Technique (Subureteric Transurethral Injection): Needle is introduced at 6 o'clock just below the ureteric orifice; bulking agent creates a firm subureteric bleb that elevates and narrows the lumen.
     • HIT / Double HIT Technique (Hydrodistension Implantation Technique): Direct injection into the intramural ureteral tunnel under hydrodistension, achieving higher coaptation rates.
   • Overall success rate: 75% to 85% for Grades I–III, but lower for Grades IV–V.

3. Ureteral Reimplantation (Ureteroneocystostomy):

   • Indications: Breakthrough febrile pyelonephritis despite compliant CAP, development of new or progressive cortical scars on DMSA scintigraphy, or persistent Grade IV–V VUR in older children.
   • Intravesical Techniques:
     • Cohen Cross-Trigonal Reimplantation: The ureter is mobilized through a transvesical incision, passed through a newly created submucosal tunnel running horizontally across the trigone above the bladder neck to the contralateral side. Success rate exceeds 95%–98%. Major drawback: future retrograde ureteric catheterization is technically challenging due to horizontal orifice orientation.
     • Politano-Leadbetter Technique: Ureter is brought in through a new hiatal entry site higher on the posterior bladder wall and tunneled downward toward the original orifice. Preserves anatomical alignment but carries risk of peritoneal entry and bowel injury.
   • Extravesical Technique (Lich-Gregoir):
     • Performed entirely extravesically (open or laparoscopic/robotic). The detrusor is sharply incised down to the intact bladder mucosa, and the ureter is laid into this muscular trough and closed over with detrusor sutures. Highly effective (>95%), but bilateral simultaneous Lich-Gregoir carries an elevated risk of transient postoperative urinary retention due to pelvic plexus neuropraxia.

---

2. Posterior Urethral Valves (PUV)

Posterior urethral valves represent the most common cause of congenital lower urinary tract obstruction (LUTO) in male infants, with an incidence of approximately 1 in 5,000 live male births.

Embryology and Valve Classification

Posterior urethral valves are obstructing congenital mucosal folds within the posterior (prostatic) urethra. Hugh Hampton Young classified PUV into three types:

• Type I (95% of cases): Two prominent sail-like mucosal folds originating from the inferior portion of the verumontanum and extending distally along the lateral walls of the posterior urethra toward the membranous urethra, representing abnormal insertion and persistent attachment of the embryological plicae colliculi.
• Type II: Mucosal folds extending proximally from the verumontanum to the bladder neck; now universally recognized as non-obstructive physiological mucosal ridges without clinical significance.
• Type III (5% of cases): A transverse diaphragm-like membrane with a small central or eccentric perforation located just below or at the level of the verumontanum.

Antenatal Presentation and Pathophysiology

High-grade obstruction during early gestation transmits hydrostatic pressure throughout the urinary tract:

• Prenatal Ultrasound Findings: Bilateral hydroureteronephrosis, a distended, thick-walled, trabeculated urinary bladder, and a dilated, elongated posterior urethra that forms the classic "keyhole" sign, suggestive of outlet obstruction.
• Oligohydramnios / Anhydramnios: Because amniotic fluid in the second and third trimesters is composed primarily of fetal urine, persistent severe LUTO causes profound oligohydramnios. This triggers Potter sequence: pulmonary hypoplasia (lethal in severe cases due to inadequate alveolar development), limb compression contractures, and classic Potter facies (flattened nose, recessed chin, low-set ears).
• VURD Syndrome: Refers to Posterior Urethral Valves, Unilateral Reflux, and Dysplasia. Massive unilateral reflux into a non-functioning dysplastic kidney acts as a high-pressure "pop-off valve," which theoretically preserves contralateral renal parenchymal development.

Postnatal Presentation & Emergency Stabilization

Postnatal presentation varies from critically ill septic neonates to infants with feeding difficulties or poor weight gain. Examination typically reveals a palpable, hard, distended bladder and a weak, dribbling, or intermittent urinary stream.

+----------------------------------------------------------------------------------------------------------+
|                                EMERGENCY NEONATAL PUV STABILIZATION                                      |
|                                                                                                          |
|  1. Immediate Bladder Decompression --> Place a 5 to 6 Fr feeding tube (NOT a balloon Foley)             |
|  2. Biochemical Resuscitation      --> Assess and correct actual electrolyte and acid-base abnormalities |
|  3. Monitor Post-Obstructive Flow  --> Measure losses and individualize fluid/electrolyte replacement    |
|  4. Diagnostic Confirmation        --> VCUG after initial drainage and stabilization                     |
|  5. Definitive Surgical Care       --> Transurethral valve ablation (at 5, 7, and 12 o'clock)            |
+----------------------------------------------------------------------------------------------------------+

[!CRITICAL] Use careful, small-calibre drainage in a neonate with suspected PUV. A secured 5–6 Fr non-balloon feeding tube is a usual first choice. Avoid a large catheter or balloon inflation in a tiny, thick-walled bladder, which can impair drainage or injure tissue. Confirm position and drainage; if urethral access is unsuccessful, obtain specialist suprapubic drainage rather than forcing a catheter.

Diagnostic Confirmation & Definitive Intervention

• MCUG Confirmation: Following drainage and hemodynamic/metabolic stabilization, perform VCUG with lateral urethral views during voiding without the catheter in situ. Diagnostic features include a dilated and elongated posterior urethra, an abrupt caliber drop at the valve level with a narrow anterior urethra, a heavily trabeculated bladder wall with pseudodiverticula, and frequent secondary VUR.
• Primary Transurethral Valve Ablation: The gold standard treatment. Performed under general anaesthesia using a miniature pediatric cystourethroscope (7.5 to 8.5 Fr). The valve leaflets are incised under direct optical visualization using a cold knife, Bugbee electrocautery, or Holmium:YAG laser at the 5, 7 and/or 12 o'clock positions. Incisions strictly spare the 6 o'clock position to protect the verumontanum, external urinary sphincter, and ejaculatory ducts.
• Cutaneous Vesicostomy (Blocksom Technique): An alternative to prolonged catheter drainage when the child is too small for endoscopy, ablation fails, or bladder/upper-tract drainage and clinical improvement remain inadequate. The choice of diversion follows the anatomy, renal course and infection status.

Long-Term Prognosis: Valve Bladder Syndrome and ESRD

Despite successful primary valve ablation, a substantial proportion develop chronic kidney disease, and EAU estimates about 20% develop end-stage renal disease. Risk varies with severity and duration of follow-up. The long-term prognosis is governed by two major factors:

1. Pre-existing Renal Dysplasia: Fixed congenital loss of nephrons sustained during critical early metanephric development in the first trimester.
2. Valve Bladder Syndrome (VBS): Chronic, progressive bladder dysfunction that persists or evolves after valve resection, driven by long-standing in utero smooth muscle hypertrophy and detrusor collagen deposition. VBS manifests in three forms:
   • Detrusor Overactivity / Hyperreflexia: Causes high storage pressures that transmit directly to the kidneys.
   • Small, Incompliant Bladder: Loss of detrusor elasticity and low functional bladder capacity.
   • Myogenic Failure: Atonic, decompensated, large-capacity bladder with poor emptying and high post-void residuals, requiring clean intermittent catheterization (CIC).

---

3. Paediatric Nocturnal Enuresis (Bed-Wetting)

Paediatric nocturnal enuresis represents one of the most common chronic conditions of childhood, affecting approximately 15% to 20% of 5-year-olds and roughly 5% of 10-year-olds, with a spontaneous resolution rate of approximately 15% per year. Despite its benign nature, it exerts profound psychosocial distress, loss of self-esteem, and familial conflict if managed inappropriately. Certification under the European Training Requirements (ETR) in Urology (p. 59) and EAU/ESPU Guidelines demands precise diagnostic classification and systematic stepped intervention.

Clinical Definition & Core Diagnostic Classification

Nocturnal enuresis is defined by the International Children's Continence Society (ICCS) as discrete episodes of involuntary urinary incontinence during sleep in children aged $\ge$ 5 years (after developmental maturation of nocturnal continence is expected).

+--------------------------------------------------------------------------------------------------------+
|                                 CLASSIFICATION OF NOCTURNAL ENURESIS                                   |
|                                                                                                        |
|  1. MONOSYMPTOMATIC (MNE)       --> Bed-wetting WITHOUT daytime LUTS or history of bladder dysfunction |
|  2. NON-MONOSYMPTOMATIC (NMNE)  --> Bed-wetting ACCOMPANIED by daytime LUTS (urgency, frequency,       |
|                                     daytime wetting, holding maneuvers) or Bladder & Bowel Dysfunction |
|  ---------------------------------------------------------------------------------------------------   |
|  • PRIMARY ENURESIS (80%)       --> Child has NEVER achieved continuous dryness for >= 6 months        |
|  • SECONDARY ENURESIS (20%)     --> Bed-wetting RELAPSES after >= 6 months of documented dryness       |
+--------------------------------------------------------------------------------------------------------+

• Monosymptomatic Nocturnal Enuresis (MNE):
  • Involuntary voiding during sleep in the complete absence of daytime lower urinary tract symptoms (no daytime urgency, frequency, daytime incontinence, hesitancy, straining, or weak stream) and without bowel dysfunction.
• Non-Monosymptomatic Nocturnal Enuresis (NMNE):
  • Enuresis occurring alongside daytime lower urinary tract symptoms:
    • Daytime frequency: Increased voiding frequency ($\ge 8$ times/day) or abnormally infrequent voiding ($\le 3$ times/day).
    • Urgency: Sudden, compelling need to pass urine.
    • Holding maneuvers: Squatting, crossing legs, standing on tiptoes, or performing the classic "Vincent's curtsy" (sitting down with the heel pressed into the perineum to compress the urethra).
    • Daytime incontinence: Involuntary daytime dampness or wetting.
    • Bladder and Bowel Dysfunction (BBD): Concomitant chronic constipation, fecal retention, or encopresis (fecal soiling). Rectal distension mechanically compresses the posterior bladder wall and provokes detrusor overactivity.
• Primary vs. Secondary Nocturnal Enuresis:
  • Primary Enuresis (~80%): The child has never achieved a period of nocturnal dryness of at least 6 consecutive months. Reflects a congenital developmental delay in neurological, hormonal, or functional bladder maturation.
  • Secondary Enuresis (~20%): Bed-wetting re-emerges after a documented dry interval of at least 6 consecutive months. Triggers are typically identifiable and include:
    • Psychological / Emotional stress: Parental divorce, arrival of a new sibling, school transition, or emotional trauma/abuse.
    • Secondary medical conditions: Acute urinary tract infection, onset of Type 1 Diabetes Mellitus (osmotic polyuria, polydipsia, weight loss), diabetes insipidus, or Obstructive Sleep Apnea (OSA) (adenotonsillar hypertrophy causing nocturnal hypoxia, sleep fragmentation, and elevated atrial natriuretic peptide [ANP] secretion that drives nocturnal polyuria).

Pathophysiological Mechanisms: The Classic Triad

Monosymptomatic nocturnal enuresis is multifactorial, arising from a failure of equilibrium among three distinct physiological pillars:

1. Nocturnal Polyuria (Insufficient Vasopressin Surge):
   • Under normal physiology, the posterior pituitary exhibits a robust circadian surge in arginine vasopressin (AVP / antidiuretic hormone [ADH]) during sleep, reducing overnight urine production to roughly 50% of daytime rates.
   • In children with enuresis driven by nocturnal polyuria, this circadian surge is blunted or absent. Overnight urine output exceeds > 130% of expected bladder capacity (EBC) for age. Up to age 12 years, use the approximation below; thereafter use an adult capacity of about 400 mL: $\text{Expected Bladder Capacity (EBC)} = (\text{Age in years} + 1) \times 30\text{ mL}$
2. Nocturnal Detrusor Overactivity / Small Functional Bladder Capacity:
   • Involuntary, uninhibited detrusor contractions occur during sleep, or the child has a functionally small bladder capacity that cannot accommodate normal volumes of nocturnal urine, triggering spontaneous evacuation at low filling volumes.
3. Arousal Failure (Sleep Arousal Dysfunction):
   • The critical final pathway: an inability of the central nervous system (thalamocortical arousal networks) to awaken the child in response to sensory afferent signals generated by a filling bladder or uninhibited detrusor contractions. Normal children awaken to void; enuretic children void while asleep.

Diagnostic Evaluation per EAU/ESPU Guidelines

Diagnostic evaluation must follow a structured, non-invasive protocol to differentiate MNE from NMNE and identify secondary etiologies:

• Comprehensive Clinical History:
  • Wetting patterns: Number of wet nights per week, number of episodes per night, volume of wetting (soaking vs dampness).
  • Screening for daytime LUTS: Voiding frequency, urgency, daytime leakage, and holding postures.
  • Bowel habits: Stool frequency, consistency (Bristol Stool Form Scale), and painful defecation to detect occult constipation.
  • Sleep history: Heavy snoring, mouth breathing, or witnessed apneas suggesting adenotonsillar hypertrophy (OSA).
  • Fluid history: Total daily fluid intake, timing of fluids, and consumption of caffeinated, high-sugar, or carbonated beverages.
• Frequency-Volume Chart (FVC) & Night-Time Diary:
  • The cornerstone of functional evaluation. Record daytime intake and voided volumes for 2–3 days, and wetting/overnight output over about 1 week. Weigh wet diapers or pads and add the first morning void to estimate nocturnal urine production.
  • Quantifies maximum daytime voided volume (to compare against expected bladder capacity for age) and confirms or refutes nocturnal polyuria.
• Physical Examination:
  • Abdominal examination for palpable fecal masses or distended bladder.
  • Inspection of external genitalia (meatal stenosis in boys, vulvovaginitis or labial adhesions in girls).
  • Neurological examination of lower extremities: Gait, deep tendon reflexes, tone, and inspection of the lumbosacral spine for cutaneous markers of occult spinal dysraphism (midline tufts of hair, sacral dimples, hemangiomas, or subcutaneous lipomas).
• Urinalysis (Dipstick Testing):
  • Indicated for sudden/secondary onset, suspected or previous UTI, unexplained polydipsia or other clinical concern; not mandatory in every otherwise typical primary MNE case.
  • Screens for: Leukocytes/nitrites (urinary tract infection), glucosuria (diabetes mellitus), proteinuria (intrinsic renal disease), and low specific gravity/osmolality (possible concentrating impairment). Abnormal screening results need clinical confirmation.

+-------------------------------------------------------------------------------------------------------+
|                      EAU/ESPU RECOMMENDATIONS ON IMAGING & URODYNAMICS IN ENURESIS                    |
|                                                                                                       |
|  Routine Renal & Bladder Ultrasound  --> NOT RECOMMENDED in uncomplicated MNE                         |
|  Micturating Cystourethrography (MCUG)--> STRICTLY NOT RECOMMENDED (Invasive, uninformative in MNE)   |
|  Invasive Urodynamics (UDS)          --> NOT RECOMMENDED in uncomplicated MNE                         |
|                                                                                                       |
|  *INDICATIONS FOR IMAGING/UDS*: Severe refractory NMNE, abnormal urinalysis, continuous incontinence, |
|  recurrent febrile UTIs, or physical/neurological abnormalities on examination.                       |
+-------------------------------------------------------------------------------------------------------+

Stepped Management Protocols: Urotherapy, Alarm, and Pharmacotherapy

Therapeutic intervention is structured according to clinical subtype and stepped guideline algorithms:

Step 1: Standard Urotherapy and Lifestyle Measures (Foundation for All Patients)

• Supportive Counselling & Demystification:
  • Reassure child and parents that enuresis is a developmental condition, not voluntary behavior or psychological defiance.
  • Strictly prohibit parental punishment, criticism, or humiliation, which exacerbates anxiety and arousal failure.
  • Implement positive reinforcement (e.g., star/sticker charts for recording wet/dry nights and adherence to routines).
• Fluid Optimization Regimen:
  • Maintain normal hydration during the day, with regular drinking especially in the morning and at lunch; reduce large drinks near bedtime and avoid caffeine.
  • Individualize evening advice rather than imposing one rigid fluid ratio or complete restriction on every child. Desmopressin has a separate, mandatory overnight fluid restriction, described below.
• Scheduled Daytime Voiding:
  • Establish regular, timed voiding every 2 to 3 hours (4 to 7 voids per day: on waking, mid-morning, lunch, mid-afternoon, dinnertime, and immediately before sleep).
  • Proper toilet posture: Relaxed pelvic floor with full foot support (use of a footstool) to ensure complete detrusor emptying without abdominal straining.
• Aggressive Management of Constipation:
  • Treat coexisting constipation aggressively with dietary fiber, behavioral toilet sitting after meals, and osmotic laxatives (polyethylene glycol / macrogol) until soft, painless daily bowel movements are established.

Step 2: First-Line Active Interventions for Monosymptomatic Nocturnal Enuresis (MNE)

Two first-line therapeutic modalities possess Level 1 evidence and Grade A recommendation under EAU/ESPU Guidelines. Selection depends on clinical presentation, family preference, and child motivation:

1. The Enuresis Alarm (Conditioning Therapy):
   • An effective option with better sustained response and less relapse than desmopressin in many studies. Initial response is often 60–80%, but relapse can occur; this is not a 70–80% guaranteed permanent cure.
   • Mechanism of Action: Conditioning and repeated awakening. A moisture-sensitive sensor attached to the underwear or a mattress pad triggers an auditory/vibratory alarm at the release of the first drops of urine. The stimulus awakens the child, triggering immediate voluntary contraction of the external sphincter, detrusor inhibition, and cessation of voiding. Over time, the conditioned reflex shifts forward, enabling the child to awaken before wetting or sleep through the night with detrusor inhibition.
   • Clinical Requirements: Requires high child and parental commitment, cooperation, and patience. The parents must initially awaken with the alarm to assist the child to the bathroom.
   • Duration: Must be continued until the child achieves 14 consecutive dry nights (typically requiring 8 to 12 weeks of continuous nightly use). Review progress during treatment; if no improvement is apparent after about 6 weeks despite correct use, reassess rather than requiring an ineffective course to continue.
2. Desmopressin (dDAVP):
   • The first-line pharmacological agent of choice, specifically indicated when nocturnal polyuria is confirmed on the bladder diary (normal functional bladder capacity with high nocturnal urine production), or when rapid symptomatic control is desired (e.g., school trips, sleepovers, or family unable to use the alarm).
   • Mechanism of Action: Synthetic analogue of arginine vasopressin that selectively binds to renal V2 receptors in collecting ducts, up-regulating aquaporin-2 water channels and concentrating urine overnight to reduce urine volume below bladder capacity.
   • Formulations & Dosing:
     • Oral Lyophilisate (MELT / sublingual tablet; 120 µg to 240 µg once daily at bedtime): Preferred over oral tablets because it dissolves instantly under the tongue without requiring water ingestion, has higher oral bioavailability, and lower food-effect variability.
     • Oral Tablets (200 µg to 400 µg once daily at bedtime): Swallowed with minimal water.
     • Intranasal Spray: STRICTLY CONTRAINDICATED in nocturnal enuresis. Nasal desmopressin is not recommended for enuresis because of its greater overdose/hyponatraemia risk. The UK removed this indication; use an appropriate oral formulation with fluid precautions.

• Treatment Duration & Discontinuation: Prescribed initially for a 3-month trial. If effective, reassess after about 3 months with a treatment break. Structured withdrawal may be tried, but evidence that tapering reliably reduces relapse is uncertain; recurrence after stopping is common.

Step 3: Second-Line & Refractory Management

• Combination Therapy (Alarm + Desmopressin):
  • Indicated for children who achieve only partial response to alarm monotherapy or desmopressin monotherapy.
• Antimuscarinics / Beta-3 Agonists (Selected Refractory Bladder Dysfunction):
  • Treat significant daytime LUTS and constipation first or concurrently. For refractory enuresis with suspected nighttime OAB or small functional capacity, a specialist may add an antimuscarinic to desmopressin; antimuscarinic monotherapy is not standard MNE treatment.
  • Check uroflow/post-void residual and ensure satisfactory emptying before bladder-relaxant therapy. Oxybutynin or another age-appropriate agent requires individualized paediatric dosing and monitoring of constipation, retention and other adverse effects.
  • Mirabegron can be considered by a paediatric specialist for selected NMNE/OAB when antimuscarinics are unsuitable. It is not a routine next step for every child with MNE; use age/weight/formulation-appropriate dosing and monitor blood pressure and residual urine.
• Tricyclic Antidepressants (Imipramine):
  • Mechanism: Increases central arousal through noradrenergic/serotonergic stimulation, combined with peripheral anticholinergic and alpha-adrenergic actions on the bladder neck.
  • Safety Profile & Limitations: Reserved strictly as a third-line agent in specialized tertiary paediatric urology clinics for refractory cases. Carries a narrow therapeutic window and high risk of fatal cardiotoxicity (ventricular dysrhythmias, QTc prolongation, heart block) in accidental or deliberate overdose. Assess cardiac risk before prescribing. Unexplained syncope, palpitations or a family history of sudden cardiac death requires electrocardiographic evaluation, with prolonged monitoring as appropriate. Follow specialist/local ECG protocols and counsel parents on secure, locked storage.

Paediatric Lower Urinary Tract Management Comparison